Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press28610.17650/2220-3478-2019-9-2-11-15LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫThe role of PET/CT with 18F-fluorodeoxyglucose in detecting the progression of colorectal cancer in asymptomatic patients with elevated level of сarcinoembryonic antigen (literature review)Роль ПЭТ/КТ с 18F-фтордезоксиглюкозой в выявлении прогрессирования колоректального рака у асимптоматических пациентов с повышенным уровнем раково-эмбрионального антигена (обзор литературы)https://orcid.org/0000-0003-3930-5998DolgushinM. B.ДолгушинМ. Б.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 23

https://orcid.org/0000-0001-7460-3267MikhaylovA. I.МихайловА. И.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

Азат Игоревич Михайлов

115478 Москва, Каширское шоссе, 23

azatmihailov@gmail.comhttps://orcid.org/0000-0002-9303-8379GordeevS. S.ГордеевС. С.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 23

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia160620199211151606201916062019Copyright ©; 2019, ABV-pressCopyright ©; 2019, АБВ-пресс2019ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/286

Positron emission tomography-computed tomography (PET/CT) with 18F-fluorodeoxyglucose in colorectal cancer is a highly sensitive imaging technique that detects malignant foci characterized by increased glucose metabolism. Currently, an increasing number of studies indicate the added value of PET/CT for the diagnosis and preoperative restaging of recurrent colorectal cancer. A special problem is a group of patients suffering from colorectal cancer, with negative or ambiguous results of radiology methods, but with an elevated level of сarcinoembryonic antigen. Many studies confirm the opinion that early use of PET/CT with 18F- fluorodeoxyglucose may have predictive value in the treatment of such patients.

Совмещенная с компьютерной томографией позитронно-эмиссионная томография (ПЭТ/КТ) с использованием 18F-фтор-дезоксиглюкозы при колоректальном раке представляет собой высокочувствительный метод визуализации, позволяющий выявлять злокачественные очаги, характеризующиеся повышенным метаболизмом глюкозы. В настоящее время все большее количество исследований показывают дополнительную ценность ПЭТ/КТ для диагностики прогрессирования колоректального рака. Особую проблему представляет группа пациентов, страдающих колоректальным раком, с отрицательными или неоднозначными результатами лучевых методов диагностики, но с повышенным уровнем раково-эмбрионального антигена. Многие исследования подтверждают мнение о том, что раннее использование ПЭТ/КТ с 18F-фтордезоксиглюкозой может иметь прогностическую ценность в лечении таких пациентов.

colorectal cancerсarcinoembryonic antigen18F-fluorodeoxyglucosepositron emission tomography combined with computed tomographyколоректальный ракраково-эмбриональный антиген18F-фтордезоксиглюкозапозитронно-эмиссионная томографиясовмещенная с компьютерной томографией. Kitajima K., Murakami K., Yamasaki E. et al. Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 2009;36(9):1388—96. PMID: 19370346. DOI: 10.1007/s00259-009-1081-5.. Kitajima K., Murakami K., Yamasaki E. et al. Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 2009;36(9):1388—96. PMID: 19370346. DOI: 10.1007/s00259-009-1081-5.Hammond K., Margolin D.A. The role of postoperative surveillance in colorectal cancer. Clin Colon Rectal Surg 2007;20(3):249-54. PMID: 20011206. DOI: 10.1055/s-2007-984869.Adam R., Pascal G., Azoulay D. et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003;238(6):871—84. PMID: 14631224. DOI: 10.1097/01sla.0000098112.04758.4e.Simmonds P.C., Primrose J.N., Colquitt J.L. et al. Surgical resection of hepatic metas-tases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006;94:982-99. DOI: 10.1038/sj.bjc.6603033. PMID: 16538219.Berger K.L., Nicholson S.A., Dehdashti F., Siegel B.A. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000;174(4):1005—8. PMID: 10749239. DOI: 10.2214/ajr.174.4.1741005.Zhu A., Lee D., Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol 2011;38(1):55—69. PMID: 21362516. DOI: 10.1053/j.semi-noncol.2010.11.012.Cipe G., Ergul N., Hasbahceci M. et al. Routine use of positron-emission tomog-raphy/computed tomography for staging of primary colorectal cancer: does it affect clinical management? World J Surg Oncol 2013;11(1):49. PMID: 23445625. DOI: 10.1186/1477-7819-11-49.Lee J.H., Lee M.R. Positron emission to-mography/computed tomography in the staging of colon cancer. Ann Coloproctol 2014;30(1):23—7. PMID: 24639967. DOI: 10.3393/ac.2014.30.1.23.Orlacchio A., Schillaci O., Fusco N. et al. Role of PET/CT in the detection of liver metastases from colorectal cancer. Radiol Med 2009;114(4):571—85. PMID: 19444590. DOI: 10.1007/s11547-009-0393-7.Travaini L.L., Trifiro G., Ravasi L. et al. Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results Eur J Nucl Med Mol Imaging 2008;35(7):1316—22. PMID: 18338164. DOI: 10.1007/s00259-008-0748-7.Benson A.B., Venook A.P., Al-Hawary M.M. et al. NCCN Guidelines Insights: Colon Cancer, version 2.2018. J Natl Compr Canc Netw 2018;16(4):359—69. PMID: 29632055. DOI: 10.6004/jnccn.2018.0021.Benson A.B., Venook A.P., Al-Hawary M.M. et al. Rectal Cancer, version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16(7):874—901. PMID: 30006429. DOI: 10.6004/jnccn.2018.0061.Steele S.R., Chang G.J., Hendren S. et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum 2015;58(8):713—25. PMID: 26163950. DOI: 10.1097/DCR.0000000000000410.Steele S.R., Chang G.J., Hendren S. et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum 2015;58(8):713—25. PMID: 26163950. DOI: 10.1097/DCR.0000000000000410.Kuker R.A., Mesoloras G., Gulec S.A. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease. Int Semin Surg Oncol 2007;4(1):17. PMID: 17623095. DOI: 10.1186/1477-7800-4-17.De Bruyne S., Van Damme N., Smeets P. et al. Value of DCE-MRI and FDG-PET/ CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 2012;106(12):1926—33. PMID: 22596235. DOI: 10.1038/bjc.2012.184.Werner M.K., Brechtel K., Beyer T. et al. PET/CT for the assessment and quantification of 90 Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases. Eur J Nucl Med Mol Imaging 2010;37(2):407—8. PMID: 19997914. DOI: 10.1007/s00259-009-1317-4.Bienert M., McCook B., Carr B.I. et al. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 2005;32(7):778—87. PMID: 15772860. DOI: 10.1007/s00259-004-1752-1.Petersen R.K., Hess S., Alavi A. et al. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. Am J Nucl Med Mol Imaging 2014;4(5):471—82. PMID: 25143865.Laurens S.T., Oyen WJ. Impact of Fluoro-deoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer. PET Clin 2015;10(3):345—60. PMID: 26099671. DOI: 10.1016/j.cpet.2015.03.007.Lu Y.Y., Chen J.H., Chien C.R. et al. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Colorectal Dis 2013;28(8):1039-47. PMID: 23407908. DOI: 10.1007/s00384-013-1659-z.Flamen P., Hoekstra O.S., Homans F. et al. Unexplained rising carcinoembry-onic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37(7):862-9. PMID: 11313174. DOI: 10.1016/S0959-8049(01)00049-1.Khan K., Athauda A., Aitken K. et al. Survival outcomes in asymptomatic patients with normal conventional imaging but raised carcinoembryonic antigen levels in colorectal cancer following positron emission tomography-computed tomography imaging. Oncologist 2016;21(12):1502—08. PMID: 27742904. DOI: 10.1634/theoncologist.2016-0222.Goldstein M.J., Mitchell E.P. Carcinoem-bryonic antigen in the staging and followup of patients with colorectal cancer. Cancer Invest 2005;23(4):338— 51. PMID: 16100946. DOI: 10.1081/CNV-58878.Graham R.A., Wang S., Catalano PJ., Haller D.G. Postsurgical surveillance of colon cancer. Preliminary cost analysis of physician examination, carcinoembry-onic antigen testing, chest X-ray, and colonoscopy. Ann Surg 1998;228(1): 59-63. PMID: 9671067.Van Cutsem E., Cervantes A., Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27(8):1386—422. PMID: 27380959. DOI: 10.1093/annonc/mdw235.Fong Y., Fortner J., Sun R.L. et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230: 309-18. PMID: 10493478.Simmonds P.C., Primrose J.N., Colquitt J.L. et al. Surgical resection of hepatic metas-tases from colorectal cancer: A systematic review of published studies. Br J Cancer 2006;94:982-99. PMID: 16538219. DOI: 10.1038/sj.bjc.6603033.Huebner R.H., Park K.C., Shepherd J.E. et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41(7):1177—89. PMID: 10914907.Zarivchatskiy M.F., Mugatarov I.N., Kamenskikh E.D. Surgical treatment of colorectal liver metastases. Annaly Khirur-gicheskoy Gepatologii = Annals of Surgical Hepatology 2018;23(1):80—7. (In Russ.).Заривчацкий М.Ф., Мугатаров И.Н., Каменских Е.Д. Хирургическое лечение метастазов колоректального рака в печень. Анналы хирургической гепатологии 2018;23(1):80—7. DOI: 10.16931/1995-5464.2018-1-80-87.Bipat S., van Leeuwen M.S., Comans E.F. et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis — metaanalysis. Radiology 2005;237:123-31. PMID: 16100087. DOI: 10.1148/radiol.2371042060.Bipat S., van Leeuwen M.S., Comans E.F. et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis — metaanalysis. Radiology 2005;237:123-31. PMID: 16100087. DOI: 10.1148/ra-diol.2371042060.Ackland S.P., Jones M., Tu D. et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005;93(11):1236—43. PMID: 16265352. DOI: 10.1038/sj.bjc.6602841.Gade M., Kubik M., Fisker R.V. et al. Diagnostic value of 18F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA. Cancer Imaging 2015;15:11. PMID: 26263901. DOI: 10.1186/s40644-015-0048-y.Moulton C., Levine M.N., Law C. et al. An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma me-tastases (CAM). J Clin Oncol 2011;29(suppl):abstr. 3520. DOI: 10.1200/jco.2011.29.15_suppl.3520.Maffione A.M., Lopci E., Bluemel C. et al. Diagnostic accuracy and impact on management of 18F-FDG PET and PET/ CT in colorectal liver metastasis: a metaanalysis and systematic review. Eur J Nucl Med Mol Imaging 2015;42(1):152-63. PMID: 25319712. DOI: 10.1007/s00259-014-2930-4.